Logo image of CYTK

CYTOKINETICS INC (CYTK) Stock Fundamental Analysis

NASDAQ:CYTK - Nasdaq - US23282W6057 - Common Stock - Currency: USD

43.43  +0.16 (+0.37%)

After market: 43.43 0 (0%)

Fundamental Rating

2

Taking everything into account, CYTK scores 2 out of 10 in our fundamental rating. CYTK was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of CYTK have multiple concerns. While showing a medium growth rate, CYTK is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CYTK had negative earnings in the past year.
CYTK had a negative operating cash flow in the past year.
In the past 5 years CYTK always reported negative net income.
CYTK had negative operating cash flow in 4 of the past 5 years.
CYTK Yearly Net Income VS EBIT VS OCF VS FCFCYTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

The Return On Assets of CYTK (-42.06%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -42.06%
ROE N/A
ROIC N/A
ROA(3y)-48.08%
ROA(5y)-38.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYTK Yearly ROA, ROE, ROICCYTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CYTK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYTK Yearly Profit, Operating, Gross MarginsCYTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

CYTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYTK has more shares outstanding than it did 1 year ago.
CYTK has more shares outstanding than it did 5 years ago.
CYTK has a better debt/assets ratio than last year.
CYTK Yearly Shares OutstandingCYTK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CYTK Yearly Total Debt VS Total AssetsCYTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

Based on the Altman-Z score of -1.15, we must say that CYTK is in the distress zone and has some risk of bankruptcy.
CYTK has a Altman-Z score of -1.15. This is comparable to the rest of the industry: CYTK outperforms 59.69% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.15
ROIC/WACCN/A
WACC10.31%
CYTK Yearly LT Debt VS Equity VS FCFCYTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

A Current Ratio of 6.17 indicates that CYTK has no problem at all paying its short term obligations.
CYTK has a better Current ratio (6.17) than 63.87% of its industry peers.
A Quick Ratio of 6.17 indicates that CYTK has no problem at all paying its short term obligations.
CYTK has a better Quick ratio (6.17) than 64.22% of its industry peers.
Industry RankSector Rank
Current Ratio 6.17
Quick Ratio 6.17
CYTK Yearly Current Assets VS Current LiabilitesCYTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

CYTK shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.49%.
Looking at the last year, CYTK shows a very strong growth in Revenue. The Revenue has grown by 145.27%.
The Revenue has been decreasing by -7.24% on average over the past years.
EPS 1Y (TTM)3.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.7%
Revenue 1Y (TTM)145.27%
Revenue growth 3Y-35.98%
Revenue growth 5Y-7.24%
Sales Q2Q%912.56%

3.2 Future

The Earnings Per Share is expected to grow by 23.34% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 263.36% on average over the next years. This is a very strong growth
EPS Next Y-3.25%
EPS Next 2Y8.99%
EPS Next 3Y21.88%
EPS Next 5Y23.34%
Revenue Next Year1451.37%
Revenue Next 2Y746.45%
Revenue Next 3Y455.66%
Revenue Next 5Y263.36%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CYTK Yearly Revenue VS EstimatesCYTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
CYTK Yearly EPS VS EstimatesCYTK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYTK. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYTK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYTK Price Earnings VS Forward Price EarningsCYTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYTK Per share dataCYTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4 -5

4.3 Compensation for Growth

A more expensive valuation may be justified as CYTK's earnings are expected to grow with 21.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.99%
EPS Next 3Y21.88%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CYTK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTOKINETICS INC

NASDAQ:CYTK (3/7/2025, 8:17:00 PM)

After market: 43.43 0 (0%)

43.43

+0.16 (+0.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)05-06 2025-05-06/amc
Inst Owners112.72%
Inst Owner Change-1.77%
Ins Owners0.44%
Ins Owner Change-0.65%
Market Cap5.14B
Analysts82.22
Price Target81.71 (88.14%)
Short Float %13.03%
Short Ratio9.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.19%
Min EPS beat(2)-6.82%
Max EPS beat(2)-3.56%
EPS beat(4)0
Avg EPS beat(4)-11.54%
Min EPS beat(4)-21.59%
Max EPS beat(4)-3.56%
EPS beat(8)0
Avg EPS beat(8)-23.91%
EPS beat(12)1
Avg EPS beat(12)-13.71%
EPS beat(16)2
Avg EPS beat(16)-10.36%
Revenue beat(2)1
Avg Revenue beat(2)395.62%
Min Revenue beat(2)-62.02%
Max Revenue beat(2)853.27%
Revenue beat(4)1
Avg Revenue beat(4)177.18%
Min Revenue beat(4)-73.51%
Max Revenue beat(4)853.27%
Revenue beat(8)2
Avg Revenue beat(8)69.61%
Revenue beat(12)3
Avg Revenue beat(12)224.4%
Revenue beat(16)4
Avg Revenue beat(16)212.83%
PT rev (1m)-2.87%
PT rev (3m)-4.03%
EPS NQ rev (1m)3.5%
EPS NQ rev (3m)-3.2%
EPS NY rev (1m)1.32%
EPS NY rev (3m)0.65%
Revenue NQ rev (1m)746.08%
Revenue NQ rev (3m)576.86%
Revenue NY rev (1m)-2.57%
Revenue NY rev (3m)-6.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 278.37
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.26
EYN/A
EPS(NY)-5.43
Fwd EYN/A
FCF(TTM)-3.38
FCFYN/A
OCF(TTM)-3.34
OCFYN/A
SpS0.16
BVpS-1.14
TBVpS-1.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.08%
ROA(5y)-38.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.98%
Cap/Sales 21.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.17
Quick Ratio 6.17
Altman-Z -1.15
F-Score6
WACC10.31%
ROIC/WACCN/A
Cap/Depr(3y)82.69%
Cap/Depr(5y)599.06%
Cap/Sales(3y)17.31%
Cap/Sales(5y)28.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.7%
EPS Next Y-3.25%
EPS Next 2Y8.99%
EPS Next 3Y21.88%
EPS Next 5Y23.34%
Revenue 1Y (TTM)145.27%
Revenue growth 3Y-35.98%
Revenue growth 5Y-7.24%
Sales Q2Q%912.56%
Revenue Next Year1451.37%
Revenue Next 2Y746.45%
Revenue Next 3Y455.66%
Revenue Next 5Y263.36%
EBIT growth 1Y-8.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.03%
EBIT Next 3Y34.29%
EBIT Next 5Y26.84%
FCF growth 1Y3.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.45%
OCF growth 3YN/A
OCF growth 5YN/A